Nothing Special   »   [go: up one dir, main page]

Skip to main content

Advertisement

Log in

Galangin for COVID-19 and Mucormycosis co-infection: a potential therapeutic strategy of targeting critical host signal pathways triggered by SARS-CoV-2 and Mucormycosis

  • Original Article
  • Published:
Network Modeling Analysis in Health Informatics and Bioinformatics Aims and scope Submit manuscript

Abstract

Mucormycosis co-infection with COVID-19 patients has a poor prognosis for fatality. However, they do not have any therapeutic choices right now. Galangin is prone to both COVID-19 and Mucormycosis, according to an ongoing study; galangin was investigated as a prospective molecular mechanism against COVID-19 with Mucormycosis co-infection to determine its functional role and underlying mechanisms of action. In SARS-COV-2 and Mucormycosis co-infection, we have conducted a series of computational approaches to identify and describe the beneficial mechanism, and pharmacological targets with therapeutic strategies of galangin against this type of co-infections. COVID-19 and Mucormycosis were characterized by pathological mechanisms, essential signaling pathways, and potential therapeutic intervention. Protein–protein interaction (PPI) was constructed for 57 common gene targets associated with co-infection. The pharmacological options were TNF (− 7.4 kcal/mol), CASP3 (− 7.3 kcal/mol), and MMP9 (− 7.7 kcal/mol) were proposed potential therapeutic targets validated through molecular docking and molecular dynamics simulation studies. Signaling pathways, molecular properties, and upstream pathway activity were also revealed in COVID-19 and Mucormycosis, along with galangin. However, treatment with galangin indicated that it could inhibit several cytokines, including TNF-α, TGF-β1, and IL-6 release which reduces inflammation and tissue injury through IL-17, HIF-1α, TGF-β, and cytokine-mediated signaling pathways. The most significant transcription factor (TF) E2F1 and miRNA hsa-miR-16-5p were identified through gene regulatory network analysis to serve as diagnostic biomarkers. However, galangin may be a possible therapeutic medication for the treatment of COVID-19 and Mucormycosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10

Similar content being viewed by others

Data Availability

The datasets supporting the conclusions of this study are included within the article and supplementary file. This data may be made available from the authors upon reasonable request.

References

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Md Habibur Rahman.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 35 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hasan, M.I., Hossain, M.A., Rahman, M.H. et al. Galangin for COVID-19 and Mucormycosis co-infection: a potential therapeutic strategy of targeting critical host signal pathways triggered by SARS-CoV-2 and Mucormycosis. Netw Model Anal Health Inform Bioinforma 12, 26 (2023). https://doi.org/10.1007/s13721-023-00421-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s13721-023-00421-6

Keywords

Navigation